Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sciclone Pharmaceuticals Inc Sees FY 2013 Guidance At Lower End Of Prior Range


Tuesday, 12 Nov 2013 06:00am EST 

Sciclone Pharmaceuticals Inc confirmed its guidance for fiscal 2013 and expects revenue at the lower end of the range between $135 and $145 million, and its non-GAAP earnings per share guidance at the lower end of the range between $0.55 and $0.61. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $140 million for fiscal 2013. 

Company Quote

8.85
-0.22 -2.43%
19 Dec 2014